Tamoxifen as first-line treatment in a premenarchal girl with juvenile breast hypertrophy.
BACKGROUND
Juvenile breast hypertrophy is uncommon and is characterized by excessive breast enlargement in the peripubertal period. The clinical entity is thought to result from increased sensitivity of mammary tissue to normal levels of circulating hormones.


METHODS
Here, we report a female patient, aged 12 years and 6 months, suffering from juvenile breast hypertrophy, who presented at the third month of symptoms and benefited from tamoxifen treatment.


CONCLUSIONS
In experienced clinics, use of tamoxifen in the treatment of juvenile breast hypertrophy during the brisk growth period may become a medical alternative to reconstructive surgery.
Demir
Korcan
K
Department of Pediatric Endocrinology, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey.
Unuvar
Tolga
T
Eren
Sanem
S
Abaci
Ayhan
A
Bober
Ece
E
D001940:Breast / Q000002:abnormalities / Q000473:pathology*; D002648:Child; D005260:Female; D006801:Humans; D006984:Hypertrophy / Q000188:drug therapy; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use*; D013629:Tamoxifen / Q000627:therapeutic use*
D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen